Biotech Values

[DonShimoda]

Over the past 12mo, TRIL has "outperformed" just over half of all bio's. Its -44% return places it 180 of 362 bio's which isn't all that bad considering its lead compound just entered the clinic, there's a complete lack of safety or efficacy data, and the risk-off environment.

When you choose equities, then healthcare, then biotechs, then small caps with a pre-clinical asset, volatility and waiting for data just come with the territory.